Biocon Biologics, a subsidiary of Biocon, has introduced Nepexto, a biosimilar to Enbrel, in the Australian market for ...

Nepexto will be promoted by Generic Health, BBL's local partner and a leading provider of high-quality generic prescription, ...

Biocon Biologics launches Nepexto, a biosimilar for autoimmune diseases like rheumatoid arthritis, in Australia. The drug ...

Etanercept is a TNF (tumor necrosis factor) inhibitor used to treat several autoimmune conditions, including rheumatoid ...

Our Standards: The Thomson Reuters Trust Principles. A U.S. judge on Monday set a fast schedule to consider the objections of relatives of those killed in two fatal 737 MAX crashes to the Justice ...

Last week, Lupin and Mylan announced that the European Commission had granted marketing authorization for their biosimilar Nepexto (etanercept) for all indications of the reference product. The ...

(RTTNews) - Mylan N.V. (MYL) and Lupin Limited said that the European Commission has granted marketing authorization for Nepexto, a biosimilar to Enbrel or etanercept, for all indications of the ...

The European Medical Agency’s Committee for Medicinal Products for Human Use (CHMP) recently reported biosimilar updates from its March 2020 meeting. At the meeting, Mylan and Lupin’s NEPEXTO ...

Biocon's subsidiary, Biocon Biologics, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in Australia for treating ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced it ...

HERTFORDSHIRE, England, PITTSBURGH and MUMBAI, India, June 4, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Lupin Limited (Lupin) today announced that the European Commission (EC) has granted ...